ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-PO856

Tacrolimus Results in Increased CTGF Expression by Human Proximal Tubule Cells and Is Associated with Donor ABCB1 3435C>T Genotype

Session Information

  • Transplantation: Basic
    October 26, 2018 | Location: Exhibit Hall, San Diego Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Transplantation

  • 1801 Transplantation: Basic

Authors

  • Knops, Noel, University Hospitals Leuven, Leuven, Belgium
  • Ramazani, Yasaman, KU Leuven , Leuven, Belgium
  • Levtchenko, Elena N., University Hospitals Leuven, Leuven, Belgium
  • Nguyen, Tri Q., UMC Utrecht, Utrecht, Netherlands
  • Kuypers, Dirk R., University Hospitals Leuven, Leuven, Belgium
Background

Clinical studies have demonstrated the importance of genetic variation in CYP3A5 and ABCB1 for tacrolimus disposition and suggested a role in the development of renal fibrosis associated with long-term tacrolimus treatment. Our aim was to explore the implications of tacrolimus exposure in a model of human proximal tubule cells incorporating genetic variation in CYP3A5 and ABCB1 on the expression of profibrotic cytokine CTGF and correlate these findings with CTGF expression in kidney allograft biopsies.

Methods

We selected 8 clones of human conditional immortalized PTC (ciPTC) with 4 different combinations of CYP3A5 (rs776746) and ABCB1 (rs1045642) genotypes. Cells were incubated with vehicle, 50 ng/ml and 300 ng/ml tacrolimus (in vivo concentration range). Quantitative RT-PCR and western blot were performed to study CTGF expression. In addition, CTGF staining was performed on protocol biopsies with a known pharmacogenetic background derived from 21 allograft recipients over a period of 2 years.

Results

CTGF mRNA and protein expression increased with tacrolimus concentration (CTGF vs. β-actin vs. vehicle at 50ng/ml: + 34.1% (95% CI: 22.3 - 45.9) and at 300 ng/ml: +45.0% (95% CI: 35.2 - 54.8); p<0.001). Subgroup analysis demonstrated 46% higher CTGF protein expression in CYP3A5 *3/*3 allele carriers vs. *1 allele carriers (p=0.047) and more than 2-fold higher CTGF expression in ABCB1 3435 TTs, while in the genetic CC/CT counterparts CTGF expression decreased (p=0.01). Immunohistochemical studies of protocol biopsies demonstrated a 37.1% increase in tubular cell CTGF staining between 3 to 24 months in kidneys from 3435 TT genotype donors, while in CC/CT donor grafts the percentage of CTGF positive tubuli remained stable (p=0.015).

Conclusion

Tacrolimus exposure in human PTCs results in a concentration-dependent increase in CTGF expression. Tacrolimus exposure for 72 hours resulted in increased CTGF expression in PTC derived from CYP3A5 *3/*3 allele carriers, and in particular with the ABCB1 3435TT genotype. Immunohistochemical studies on protocol biopsies confirm increasing CTGF expression over time in donor kidneys with the ABCB1 3435TT genotype.

Funding

  • Government Support - Non-U.S.